CAR T-cell therapy for certain advanced solid tumors
Treatments studied
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called GCAR1, which uses your own immune cells (T-cells) to find and attack cancer cells that have a specific marker called GPNMB. It is for people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if this therapy can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancer types: alveolar soft part sarcoma, renal cell carcinoma (not clear cell), or triple negative breast cancer.
- Your tumor must have high levels of a protein called GPNMB, which will be checked in a lab.
- You must have tried at least one prior systemic treatment (for renal cell carcinoma, this must include an immunotherapy and a targeted drug; for breast cancer, it must include certain chemotherapies).
- You must be at least 15 years old (for sarcoma) or 18 years old (for breast or kidney cancer).
- You must be in generally good health, with a life expectancy of at least 6 months and be able to have cells collected from your blood.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests an experimental cell therapy (CAR T-cells) for people with advanced pancreatic cancer, sarcoma, or breast cancer that has not responded to standard treatments. It may be an option if you have tried other therapies and are looking for a new approach.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
Hear when a new Alveolar Soft Part Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.